PALB2 ChAM acetylation mapping in human cells
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: 
Marjorie Fournier
LAB HEAD: Fumiko Esashi
PROVIDER: PXD014678 | Pride | 2023-03-10
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| PALB2ChAMacetylation.msf | Msf | |||
| PALB2ChAMacetylation.raw | Raw |
Items per page: 5 1 - 2 of 2 |
Publications
KAT2-mediated acetylation switches the mode of PALB2 chromatin association to safeguard genome integrity.
Fournier Marjorie M Rodrigue Amélie A Milano Larissa L Bleuyard Jean-Yves JY Couturier Anthony M AM Wall Jacob J Ellins Jessica J Hester Svenja S Smerdon Stephen J SJ Tora László L Masson Jean-Yves JY Esashi Fumiko F
eLife 20221021
The tumour suppressor PALB2 stimulates RAD51-mediated homologous recombination (HR) repair of DNA damage, whilst its steady-state association with active genes protects these loci from replication stress. Here, we report that the lysine acetyltransferases 2A and 2B (KAT2A/2B, also called GCN5/PCAF), two well-known transcriptional regulators, acetylate a cluster of seven lysine residues (7K-patch) within the PALB2 chromatin association motif (ChAM) and, in this way, regulate context-dependent PAL ...[more]
Similar Datasets
Project description:PArtner and Localizer of BRCA2 (PALB2) is essential to maintain genome stability in human cells. Upon DNA damage by double DNA strand breaks, PALB2 is required to repair DNA by homologous recombination. In undamaged conditions, PALB2 protects coding regions, by preventing DNA stress due to collisions between transcription and replication machineries. PALB2 associates with chromatin, which is essential to fulfill its function in genome stability maintenance, however molecular mechanisms regulating PALB2 chromatin association remain unknown. In our previous published study describing the KAT2A/B(GCN5/PCAF)-acetylome (Fournier et al., Nat.Comm. 2016, doi: 10.1038/ncomms13227) we have identified PALB2 as an acetylated protein target of the acetyltransferases KAT2A (GCN5) and KAT2B (PCAF) in vivo. KAT2A/B-acetylated sites of PALB2 were mapped within its DNA/Chromatin association domain. In this current study, we have conducted in vitro acetyltransferase (AT) assays, by mixing purified recombinant GST-tagged PALB2 full-length (FL) and PALB2 fragment P2.2 which associates with DNA/chromatin (from residues 295-610), with Flag-PCAF, Flag-GCN5 and Flag-GCN5 catalytic mutant (mut), followed by proteomics analysis to map PALB2 acetylated lysines by KAT2A(GCN5) and KAT2B(PCAF) in vitro. PALB2 FL and P2.2 alone, or PALB2 FL and P2.2 mixed with GCN5 catalytic mutant, were used as negative controls.
2023-03-10 | PXD014681 | Pride
Project description:Changes in acetylation of histone H4 are a common hallmark of cancer cells. In leukemia cells, histone H4 is characterized by loss of K16 mono-acetylation. Bromodomain proteins specifically recognize acetylated lysines and have been used as a target for anti cancer drug, JQ1 and iBET. Although acetylation and de-acetylation of histone H4 have been shown to have big impact in cancer cells, little attention has been focused on histone H4-acetylation at a genome level. To uncover potential epigenetic role of hyper-acetylated histone H4 at a genome-wide level in cancer cell, we generated a novel monoclonal antibody specifically recognizing histone H4 with at least two acetylated lysine residues (H4K5ac+K8ac). At the genome-wide level, hyper-acetylated histone H4 is associated with promoter and regulatory element (active enhancer, eRNA and super enhancer). We show that diacetylation at K5 and K8 of histone H4 co-localizes H3K27ac and BRD2 in the majority of active enhancer and promoters. However BRD2 has a stronger association with H4K5acK8ac. Furthermore we identified two specific chromatin states, which separately contain either H3K27ac or acetylated histone H4. Although JQ1 led to global reduction of BRD2 binding on the chromatin, only local changes of histone H4 multi-acetylation were observed upon BET inhibition by JQ1
2018-06-04 | GSE113714 | GEO
Project description:During the post-meiotic phase of spermatogenesis, transcription is progressively repressed as the nuclei of haploid spermatids are compacted through a dramatic chromatin reorganization involving hyper-acetylation and replacement of most histones with sperm-specific protamines. Although BRDT has been shown to function in transcription as well as histone removal in post-meiotic spermatids, it is unknown whether other BET family proteins play a role. Immunofluorescence of mouse testes revealed BRD4 in a complete ring around the nuclei of spermatids containing hyper-acetylated histones. The BRD4 ring lies directly adjacent to the acroplaxome, or the cytoskeletal base of the acrosome, and does not form in acrosomal mutant mice. ChIP sequencing in round spermatids revealed enrichment of BRD4 and acetylated histone H3 and H4 at the promoters of active genes. GO Term analysis showed that BRD4 and BRDT bind to distinct subsets of spermatogenesis-specific genes. Association of BRD4 with Cyclin T1 decreases as spermatogenesis progresses despite a persistence of association with acetylated H4. Moreover, acetylated histones are removed from the condensing spermatid nucleus in a wave following the progressing acrosome. These data provide evidence for an interesting mechanism in which BRD4 and perhaps acetylated histones are removed from the spermatid genome via the progressing acrosome as transcription is repressed. Single replicates each of Brd4, H3K9me3, H3K9ac, H4K5ac, H4K8ac, H4K12ac, H4K16ac, H4Kac (pan-acetyl antibody), and input in mouse round spermatid cells; input is used to control for local sonication efficiency bias.
2015-03-06 | E-GEOD-56526 | biostudies-arrayexpress
Project description:The histone acetyl-reader BRD4 is an important regulator of chromatin structure and transcription, yet factors modulating its activity have remained elusive. Here we describe two complementary screens for genetic and physical interactors of BRD4, which converge on the folate pathway enzyme MTHFD1. We show that a fraction of MTHFD1 resides in the nucleus, where it is recruited to distinct genomic loci by direct interaction with BRD4. Inhibition of either BRD4 or MTHFD1 results in similar changes in nuclear metabolite composition and gene expression, and pharmacologic inhibitors of the two pathways synergize to impair cancer cell viability in vitro and in vivo. Our finding that MTHFD1 and other metabolic enzymes are chromatin-associated suggests a direct role for nuclear metabolism in the control of gene expression. BRD4 is an important chromatin regulator with roles in gene regulation, DNA damage, cell proliferation and cancer progression1-4. The protein is recruited to distinct genomic loci by the interaction of its tandem bromodomains with acetylated lysines on histones and other nuclear proteins5. There, BRD4 acts as a transcriptional activator by P-TEFb-mediated stimulation of transcriptional elongation6. The activating function of BRD4 on key driver oncogenes like MYC have made this epigenetic enzyme an important therapeutic target in both BRD4 translocated and BRD4 wild-type cancers3,7-12, and at least seven bromodomain inhibitors have reached the clinical stage13. Genome-wide studies have identified the role of BRD4-induced epigenetic heterogeneity in cancer cell resistance14, and factors defining BRD4 inhibitor response15,16. However, despite its clinical importance and the broad role of BRD4 in chromatin organization, surprisingly little is known about factors that are directly required for BRD4 function. To systematically expand the list of known BRD4 interactors5 and to characterize proteins directly required for BRD4 function, we developed a strategy of two complementary screens for genetic and physical partners of BRD4. The two approaches converge on a single factor, methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). Our description of a transcriptional role for this C-1-tetrahydrofolate synthase highlights a direct connection between nuclear folate metabolism and cancer regulation.
2019-04-04 | PXD013090 | Pride
Project description:In this study we focus on the MYST-type acetyltransferase MOF (males-absent-on-the-first, KAT8), which is the effector enzyme of two transcription regulator complexes in Dro-sophila. As part of the male-specific-lethal dosage compensation complex (MSL-DCC, or DCC for short), the enzyme is targeted to transcribed genes on the X chromosome, where it acetylates H4K16 to unfold the chromatin fiber to boost transcription (15-17). In the context of the NSL complex (16) MOF has been reported to acetylate different combina-tions of histone H4 lysines 5, 8, 12 and 16 at promoters in different cells, illustrating the potential of complex subunits to modulate substrate specificity (18-21). Defining the substrate selectivity of KATs in vivo poses several challenges (1). The intrin-sic substrate selectivity of enzymes may be modulated by its molecular environment, be it the complex assembly or the chromatin context. Redundant activities of different en-zymes, indirect effects and the action of lysine deacetylases (KDACs) may occlude the consequences of loss-of-function manipulation. Furthermore, the specificity of the anti-bodies that are commonly used to detect distinct acetylated lysines in histones may be compromised due to low-level off-target effects, interference of modifications next to acetylated lysines, and the tendency of Kac-antibodies to react with relaxed selectivity with oligo-acetylated histone tails (22-25). A more reliable strategy involves the detection of modified histone peptides by mass spectrometry, which unequivocally detects individ-ual modifications and defined combinations of modifications and has a much better dy-namic range than traditional Western blotting (26-30). In a complementary approach one may determine the intrinsic substrate selectivity of defined recombinant enzymes and KAT complexes in biochemical assays (31). We re-cently reconstituted a recombinant MOF-containing core DCC (here termed ‘4-MSL’, since it contains the subunits MOF, MSL1, MSL2 and MSL3 (32)) and now report on a study of its substrate selectivity on recombinant nucleosome arrays. Pilot experiments using traditional Western blotting of diagnostic antibodies suggested that, in addition to the expected H4K16 acetylation, H4K12 was modified. Since this finding disagrees with the prevailing view that the DCC selectively acetylates H4K16, we applied the targeted mass spectrometry described in (26) to our in vitro reactions, focusing on acetylation of the H4 N-terminus. We compared the acetylation reaction of the 4-MSL complex with another MYST enzyme, dTip60 (KAT5), in the context of a trimeric complex, akin to the yeast piccolo NuA4 complex, which is thought to have a more relaxed lysine selectivity on the H4 N-terminus (33-35). We found that during short reaction times, the 4-MSL complex acetylated H4K16 with excellent selectivity, while the dTip60piccolo complex preferentially modified H4K12. To our surprise, we also observed that during longer incubations the 4-MSL complex progres-sively acetylated K12, K8 and K5, leading to a complex mixture of oligo-acetylated H4. Mathematical modeling suggests that MOF recognizes and acetylates H4K16 with high selectivity, but remains bound to the substrate and continues to acetylate more N-terminal H4 lysines in a processive manner. Because the MSL-DCC in vivo contains long, non-coding roX RNA (15,36-38), we ex-plored whether RNA affected the specificity of the reaction. We observed that the addi-tion of RNA to the HAT reaction improves the specificity of the reaction and suppresses the generation of oligo-acetylated forms, possibly by reducing the dwell time of the en-zyme on the nucleosome substrate. The comparison of MOF and dTip60 activities in the context of recombinant HAT com-plexes revealed significant differences in activity and specificity. Our study describes a powerful experimental approach and conceptual framework for the analysis of physiolog-ically relevant components that modulate intrinsic activities.
2024-02-13 | PXD046636 | Pride
Project description:Vascular stability and tone are maintained by contractile smooth muscle cells (VSMCs). However, injury-induced growth factors stimulate a contractile-synthetic phenotypic modulation which increases susceptibility to abdominal aortic aneurysm (AAA). As a regulator of embryonic VSMC differentiation, we hypothesised that Thymosin β4 (Tβ4) may function to maintain healthy vasculature throughout postnatal life. This was supported by the identification of an interaction with Low density lipoprotein receptor related protein 1 (LRP1), an endocytic regulator of PDGF-BB signalling and VSMC proliferation. LRP1 variants have been implicated by genome-wide association studies with risk of AAA and other arterial diseases. T4-null mice displayed aortic VSMC and elastin defects, phenocopying LRP1 mutants, and their compromised vascular integrity predisposed to Angiotensin II-induced aneurysm formation. Aneurysmal vessels were characterised by enhanced VSMC phenotypic modulation and augmented platelet-derived growth factor (PDGF) receptor (PDGFR)β signalling. In vitro, enhanced sensitivity to PDGF-BB, upon loss of Tβ4, associated with dysregulated endocytosis, with increased recycling and reduced lysosomal targeting of LRP1-PDGFRβ. Accordingly, the exacerbated aneurysmal phenotype in T4-null mice was rescued upon treatment with the PDGFRβ antagonist, Imatinib. Our study identifies Tβ4 as a key regulator of LRP1 for maintaining vascular health and provides insights into the mechanisms of growth factor-controlled VSMC phenotypic modulation underlying aortic disease progression.
2021-05-21 | PXD024162 | Pride
Project description:Urea-based buffers can induce carbamylation artefacts. Here we report that carbamylation of lysine residues resembles the structure of acetylated lysines (K-ac) and compete during K-ac immunoaffinity purification. We propose an alternative strategy using an ionic detergent which improves significantly the selectivity and efficiency of K-ac affinity immuno-purifications.
2017-01-11 | PXD003701 | Pride
Project description:Identification of interacting partners of the Partner and Localizer of BRCA2 (PALB2), essential regulator of DNA repair by homologous recombination. Interacting partners of PALB2 were purified by GFP pull down from asynchronous HEK293 Flp-In T-REx cells, exogenously expressing Flag-EGFP tagged PALB2 at a similar level than the endogenous PALB2 level. Before GFP pull down, whole cell protein extracts were pre-cleared on IgG agarose beads to decrease binding of non-specific proteins during GFP pull down. GFP pull down were performed using GFP-Trap agarose beads (Chromotek) and washed at low salt concentration (150mM NaCl), to maintain interactions of low affinity binding protein partners. As a negative control, Flag-EGFP interacting proteins were purified, following the same protocol as described for the purification of Flag-EGFP PALB2 interacting proteins. Experiments were performed in triplicate.
2017-07-18 | PXD006391 | Pride
Project description:BRD4 is an epigenetic reader known to bind to acetylated lysines on histones and transcription factors, and it has been implicated in recruiting transcriptional machinery to promote differentiation gene expression in multiple cellular contexts. This activity is dependant on proper BRD4 localization to active promoters and enhancers, which is dependant on a variety of factors including lineage determining transcription factors (LDTFs). We found BRD4 to be necessary for epidermal differentiation, during which it shares many chromatin binding sites with a variety of epidermal lineage-determining transcription factors (LDTF's). BRD4 also regulates a similar differentiation related transcriptional program with the epidermal LDTF KLF4.
2020-04-03 | GSE140992 | GEO
Project description:In this study we have used ChIP followed by high throughput sequencing to profile the genome-wide recruitment of wildtype and non-oligomerizing Groucho (Gro) at high resolution in single cell types (Kc167 and S2R+) using Drosophila cell culture. Our results reveal that Gro is typically recruited to discrete peaks in active chromatin and that blocking Gro oligomerization does not change the width of the peaks to which it is recruited. We have also investigated acetylated histone H3 and H4 and RNA polymerase II profiles around Gro binding sites, along with gene expression, in wildtype, Gro knockdown, Gro-GFP transfected, and non-oligomerizing Gro-GFP transfected Kc167 cells and found that Gro associates with chromatin containing hypoacetylated histones and frequently overlaps the transcription start sites of expressed genes that exhibit strong RNA polymerase pausing.
2014-09-12 | E-MTAB-2316 | biostudies-arrayexpress